Thromboembolic Risks of Non-Factor Replacement Therapies in Hemophilia

Hamostaseologie. 2017;37(4):307-310. doi: 10.5482/20170004. Epub 2017 Dec 28.
No abstract available

Publication types

  • Review

MeSH terms

  • Acetylgalactosamine / therapeutic use*
  • Adolescent
  • Adult
  • Antibodies, Bispecific / adverse effects*
  • Antibodies, Bispecific / therapeutic use
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Blood Coagulation Factors / adverse effects*
  • Blood Coagulation Factors / therapeutic use
  • Congresses as Topic
  • Factor VIIa / adverse effects*
  • Factor VIIa / therapeutic use
  • Hemophilia A / blood
  • Hemophilia A / therapy*
  • Hemophilia B / blood
  • Hemophilia B / therapy*
  • Hemorrhage / blood
  • Hemorrhage / therapy
  • Humans
  • RNA, Small Interfering / therapeutic use*
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Thromboembolism / chemically induced*

Substances

  • Antibodies, Bispecific
  • Antibodies, Monoclonal, Humanized
  • Blood Coagulation Factors
  • RNA, Small Interfering
  • Recombinant Proteins
  • fitusiran
  • prothrombin complex concentrates
  • emicizumab
  • recombinant FVIIa
  • Factor VIIa
  • Acetylgalactosamine